# US 2018/0021309 A1 · Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021309 A1
- Document ID: US20180021309A1
- Status: Published application
- Kind: A1
- Application number: 15/668,377
- Filed: 2017-08-03
- Published: 2018-01-25
- Earliest claimed: 2010-02-04
- Assignees: Laboratorios Del Dr. Esteve, S.A.
- Applicants: Laboratorios Del Dr. Esteve, S.A.
- Inventors: José Miguel VELA HERNANDEZ; Daniel ZAMANILLO-CASTANEDO
- Web page: https://patentgrep.com/patent/US20180021309A1

## CPC

- A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (1) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 1

A method of treatment of a patient suffering from pain developed as a consequence of surgery, or a patient likely to suffer pain as a result of a surgical treatment, which comprises administering to the patient an amount of a pharmaceutical combination, the pharmaceutical combination comprising:
i) an opioid or opiate selected from the group consisting of morphine or a structural derivative thereof, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine; and
ii) a sigma ligand, wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof, which amounts in combination are effective to treat the pain of the patient.

### Claim 2 (depends on 1)

The method of claim 1, comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

### Claim 3 (depends on 1)

The method of claim 1, wherein the opiate is selected from the group consisting of morphine, hydromorphone, oxymorphone, desomorphine, diacetylmorphine, nicomorphine, dipropanoylmorphine, benzylmorphine, ethylmorphine, codeine, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine.

### Claim 4 (depends on 4)

The method of claim 4, wherein the opioid or opiate and the sigma ligand are part of the same medicament formulation.

### Claim 5 (depends on 1)

The method of claim 1, comprising administering the opioid or opiate and the sigma ligand simultaneously.

### Claim 6 (depends on 1)

The method of claim 1, wherein the combination comprises a first unit and a second unit, the first unit comprising the opioid or opiate and the second unit comprising the sigma ligand.

### Claim 7 (depends on 6)

The method of claim 6, comprising administering the opioid or opiate and the sigma ligand simultaneously.

### Claim 8 (depends on 6)

The method of claim 6, comprising administering the opioid or opiate and the sigma ligand separately or sequentially.

### Claim 9 (depends on 8)

The method of claim 8, comprising administering the opioid or opiate, followed by administering the sigma ligand.

### Claim 10 (depends on 9)

The method of claim 9, comprising administering the sigma ligand, followed by administering the opioid or opiate.

### Claim 11 (depends on 1)

The method of claim 1, comprising administering the combination prior to the surgery or the surgical treatment.

### Claim 12 (depends on 11)

The method of claim 11, comprising administering the combination from about 30 minutes to about 24 hours prior to the surgery or the surgical treatment.

### Claim 13 (depends on 1)

The method of claim 1, comprising administering the combination subsequent to the surgery or the surgical treatment.

### Claim 14 (depends on 13)

The method of claim 13, comprising administering the combination from about 1 hour to about 36 hours subsequent to the surgery or the surgical treatment.

### Claim 15 (depends on 14)

The method of claim 14, comprising administering the combination from about 3 to about 4 hours subsequent to the surgery or the surgical treatment.

### Claim 16

A method for potentiating the analgesic effect of an opioid or opiate in a patient while also decreasing the dependency of the patient induced thereby when said opioid or opiate is administered in the prevention or treatment of pain that is a consequence of surgery, wherein said opioid or opiate is selected from the group consisting of morphine or a structural derivative thereof, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine, which comprises administering to the patient a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof.

### Claim 17 (depends on 1)

The method of claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

### Claim 18 (depends on 1)

The method of claim 1, wherein the opiate is selected from the group consisting of morphine, hydromorphone, oxymorphone, desomorphine, diacetylmorphine, nicomorphine, dipropanoylmorphine, benzylmorphine, ethylmorphine, codeine, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine.
